Preparing for a kidney transplant: Medical nephrectomy in children with nephrotic syndrome

Eefke Vos | Linda Koster-Kamphuis | Nicole C. A. J. van de Kar | Charlotte M. H. H. T. Bootsma-Robroeks | Elisabeth A. M. Cornelissen | Michiel F. Schreuder

Department of Pediatric Nephrology, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, The Netherlands

Correspondence
Michiel F. Schreuder, Department of Pediatric Nephrology, Radboudumc Amalia Children’s Hospital, 804, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Email: michiel.schreuder@radboudumc.nl

Abstract
Nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and general edema. These symptoms may persist in children who reach ESRD, which is unfavorable for the patient's allograft outcome. In addition, this may hamper early diagnosis of a relapse after transplantation. Surgical bilateral nephrectomy is often considered for that reason, but medical nephrectomy may be a less invasive alternative. In this retrospective single-center case series, we identified all children on dialysis with ESRD due to nephrotic syndrome in which a medical nephrectomy was attempted before kidney transplantation between 2013 and 2018. Outcome was measured by urine output and serum albumin levels. Eight patients with either congenital nephrotic syndrome or focal segmental glomerular sclerosis were included in the study. All patients received an ACE inhibitor as drug of first choice for medical nephrectomy, to which 5 patients responded with oligoanuria and a significant rise in serum albumin, and 3 patients responded insufficiently. In 1 of these 3 patients, diclofenac was added to the ACE inhibitor, with good result. In the other 2 patients, indomethacin was initiated without success, and surgical bilateral nephrectomy was performed. Overall, 6/8 patients had a successful medical nephrectomy and did not need surgical nephrectomy. No recurrence of nephrotic syndrome was found after kidney transplantation in all but one. Medical nephrectomy with ACE inhibitors and/or non-steroidal anti-inflammatory drugs is a safe and non-invasive therapy to minimize proteinuria in children with ESRD due to nephrotic syndrome before kidney transplantation. We suggest that this strategy should be considered as therapy before proceeding with surgical nephrectomy.

Keywords
ACE inhibitors, kidney transplantation, medical nephrectomy, nephrotic syndrome, NSAIDs

Abbreviations: ACE, angiotensin-converting enzyme; CNS, congenital nephrotic syndrome; ESRD, end-stage renal disease; FSGS, focal segmental glomerular sclerosis; NSAIDs, non-steroidal anti-inflammatory drugs.
1 | INTRODUCTION

Nephrotic syndrome is a glomerular disorder that is defined by massive proteinuria, hypoalbuminemia, and general edema. Children with nephrotic syndrome mostly respond well to steroids and have a favorable prognosis. In contrast, therapy-resistant nephrotic syndrome generally results in ESRD within a few years.1,2

Kidney transplantation in patients with active nephrotic syndrome poses 2 major risks. First of all, hypoalbuminemia leads to an unfavorable circulatory status and an increased risk of thromboembolic events, both resulting in major risks for the renal transplant.3,4 In fact, optimal hydration is the most important perioperative intervention to ensure graft function.5 Second, nephrotic syndrome may relapse after transplantation. Early detection of proteinuria after transplantation is vital to start treatment for such relapses in order to improve prognosis. “Contamination” of the urine with proteinuria from the native kidneys may hinder such early detection. Furthermore, proteinuria may also indicate rejection of the transplant kidney, for which prompt diagnosis and treatment are also necessary.6 Ponticelli et al have shown that renal survival rates of patients with proteinuria are worse in comparison with non-proteinuric patients.7 In fact, the quantity of proteinuria is a reliable predictor of the allograft outcome.7

In order to improve the circulatory status during and after renal transplantation and allow for early detection of proteinuria of the transplant kidney, treatment to stop the native proteinuria is often needed. Currently, the treatment of choice in such patients is surgical nephrectomy.2,8 This leads to at least one additional operation in these patients, which is known to have high rates of morbidity and even mortality (up to 2.0%).9,10 A less invasive but successful therapy is bilateral renal artery embolization, which may have severe side effects, such as severe flank pain and fever, and requires specific interventional skills that may not be readily available.11-13

ACE inhibitors and NSAIDs have antiproteinuric effects and are used as such in patients with (congenital) nephrotic syndrome.14-16 Case reports show that non-invasive nephrectomy by using NSAID and/or ACE inhibitors may have an immediate effect on urine output and proteinuria, resulting in a sharp rise of serum protein levels.14,17,18 Unfortunately, little effect was seen in some other reports.13,19

In our center, we have used medical nephrectomy as a first-line option in children with therapy-resistant nephrotic syndrome on dialysis during the workup for renal transplantation. Our retrospective case study investigated the feasibility and safety of the use of ACE inhibitors and/or NSAIDs instead of surgical nephrectomy or renal artery embolization in order to achieve medical nephrectomy in a safe non-invasive way in patients with persistent severe proteinuria in the workup toward renal transplantation.

2 | PATIENTS AND METHODS

In this single-center retrospective case study, we did a data search of all pediatric renal transplant candidates with ESRD due to nephrotic syndrome in the period 2013-2018. This period was chosen for reasons of data availability in the digital hospital data system. Of these patients, we identified those who were treated with medication in order to induce a medical nephrectomy prior to renal transplantation. Such patients received an ACE inhibitor and/or NSAID after starting dialysis. The dosage of the medication was based on body weight and blood pressure, and adjusted based on the anti-diuretic effect, blood pressure, and side effects such as liver function tests. In all cases, the medication was stopped at least 1 day before kidney transplantation.

Patient characteristics extracted from electronic patient records were date of birth and diagnosis, gender, weight, date of medical nephrectomy, date of dosage changes of ACE inhibitor and/or NSAIDs, and date of kidney transplantation. Furthermore, we extracted clinical and genetic diagnosis, medication type and dosages pre- and post-surgery, and complications like thrombosis. Clinical and laboratory results extracted were blood pressure, urine output, amount of proteinuria if measured, and serum albumin levels before and after the start of the medical nephrectomy.

2.1 | Statistical analysis

Descriptive analyses were performed using SPSS, version 22.0 (IBM). Results are expressed as median with range and counts with percentages.

3 | RESULTS

3.1 | Demographics

Eleven pediatric patients with nephrotic syndrome who were prepared for renal transplantation were identified in this study. Three patients were not started on ACE inhibitors for medical nephrectomy, because of severe illness (N = 1, surgical nephrectomy was performed to stabilize the patient due to extensive fluid overload) and therapy-resistant malignant hypertension (N = 2). Eight patients did receive medication to induce a medical nephrectomy prior to renal transplantation (Figure 1 and Table 1). The diagnosis leading to ESRD was CNS due to a mutation in the NPHS1 gene (n = 2) or NPHS2 gene (n = 3), and FSGS without a proven genetic basis (n = 3). All patients were on dialysis prior to the kidney transplantation, whereof 4 patients on hemodialysis and 4 on peritoneal dialysis.

Table 1 shows the demographics, preoperative characteristics, and post-operative outcome of these patients. The median age at transplantation was 5.7 (range 3.4-10.0) years with a median age of 4.2 (range 2.3-9.4) years at the start of medical nephrectomy, 2.1 (range 0.04-3.67) years after diagnosis.

Currently, 7 of the 8 patients had a successful kidney transplantation (6 living and 1 post-mortem heart beating), whereof 6 patients without recurrence of nephrotic syndrome despite keeping their native kidneys. One patient was still on hemodialysis waiting for kidney transplantation, and 1 patient had a therapy-resistant recurrence of the disease after transplantation and had to restart dialysis.
3.2 | Medical nephrectomy

Figure 1 shows a flow diagram of the medication used for medical nephrectomy in our patients. The medication dosages are presented in Table 1. All eight patients received enalapril with a median daily starting dose of 0.09 mg/kg (range 0.07-0.31 mg/kg). Adjustments in dosage were made based on blood pressure and urine output in the individual patients, with a median maximum daily dose of 0.30 mg/kg (range 0.03-0.76 mg/kg). Reasons to lower or stop enalapril were hypotension or persistent significant urine output despite increases in the dose. Two patients received indomethacin (1.0 and 2.0 mg/kg/day, respectively) after unsuccessful medical nephrectomy with enalapril: Patient 3 was taken off enalapril after 2.5 months for hypotension, after which indomethacin was started; patient 8 was treated with enalapril for 14 months when indomethacin was added. In both patients, medical nephrectomy with indomethacin had to be stopped due to elevated transaminases after 1 and 6 months, respectively. In 1 patient, diclofenac was added to enalapril because of persistent proteinuria and significant urine output despite an acceptable serum albumin level of 34 g/L. It was started at a dose of 50 mg 3 times a week after the hemodialysis session and increased to 100 mg 3 times a week.

Albumin levels increased or stayed in within normal range in all patients (Table 2). After starting enalapril albumin levels increased from a median of 18 (range 11-28) g/L to a median of 31 (range 21-36) g/L. With indomethacin albumin levels increased from a median of 25 (range 21-29) g/L to a median of 29 (27-31) g/L. The patient who received diclofenac in addition to enalapril showed no change in serum albumin levels, as the albumin level before start was already 34 g/L.

In all patients, the medication for medical nephrectomy was stopped at least 1 day before kidney transplantation.

In 6 patients, medical nephrectomy prior to renal transplantation was successful. In two patients, treatment was unsuccessful and surgical bilateral nephrectomy was performed as preparation for renal transplantation. Both these patients were diagnosed with NPHS1 mutations. In 1 patient, medical nephrectomy failed because of side effects (enalapril because of hypotension and indomethacin because of elevated transaminases). The other patient had no relevant change in urine output and proteinuria despite enalapril and indomethacin, and medication dose could not be increased because of a low blood pressure and a slight increase in liver function tests.

3.3 | Side effects

The only side effect of enalapril seen was hypotension. In 3 cases, ceasing other anti-hypertensive drugs was enough to normalize blood pressure, in 1 case a reduction in dosage was sufficient and in 2 cases enalapril needed to be stopped. In both patients that were started on indomethacin, liver function tests were elevated as a side effect, leading to cessation of treatment and subsequent surgical bilateral nephrectomy. In contrast, there were no side effects seen in the patient that was treated with diclofenac in combination with enalapril. After transplantation, no thrombosis, delayed graft function, hypotension, or need of diuretics was noted.
DISCUSSION

Our case series showed that controlled medical nephrectomy in children with ESRD due to nephrotic syndrome is a feasible and safe non-invasive treatment in the preparation of renal transplantation. ACE inhibitors seem to be the drug of first choice because of the high success rate and mild side effects in a dosage up to 0.30 mg/kg per day. In contrast, indomethacin has a low success rate and considerable side effects, that is, hepatic impairment, which makes its use questionable for medical nephrectomy, even in low doses, in our experience. No conclusion can be drawn with regard to diclofenac since it was only given to one patient in our institution.

Previous case reports evaluating medical nephrectomy observed variable results (for an overview, see Table 3).\textsuperscript{12-14,17,19} In all reports, ACE inhibitors, indomethacin, or another NSAID were used to achieve an acceptable circulatory state before transplantation. Dosages used in these case reports are 2 mg/kg/day to 14 mg/kg/day of indomethacin, a maximum of 5 mg/kg/day of captopril, and a dose of 1 mg/kg/day of quinapril. A possible reason for the difference in outcome between some of the previous case reports and our experience could be the difference in type of nephrotic syndrome. Another reason could be the fact that in our center all patients were on dialysis, which we used as an effective method to achieve intravascular volume depletion in addition to the medical nephrectomy. The differences in dosage are not likely the cause, as we used lower dosages in our study compared to the above-mentioned case reports.

Of the 11 patients identified, 5 underwent surgical nephrectomy. The complication rate in these patients was favorable, with no mortality and only minor morbidity, mainly related to the surgery. As described, 2 patients were already treated with anti-hypertensive agents, including ACE inhibitors, and had a surgical nephrectomy for uncontrolled blood pressure. In addition, in 1 patient surgical nephrectomy was performed to stabilize the patient due to extensive fluid overload, in whom it was deemed impossible to perform a medical nephrectomy. These cases illustrate that surgical nephrectomy may be a preferred option, and an individualized consideration of the treatment options should be made.

Another option to shut down the kidneys is by bilateral renal artery embolization. The reported success rate is higher than in medical nephrectomy, but side effects can be severe.\textsuperscript{11-12,19} Side effects that have been previously described are fever and challenging flank pain, requiring narcotic analgesics in combination with epidural

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|}
\hline
\textbf{Disease} & 1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 \\
\hline
\textbf{Mutation} & CNS & CNS & CNS & FSGS & CNS & FSGS & FSGS & CNS \\
\hline
\textbf{Gender (M/F)} & M & F & M & M & M & F & M & F \\
\hline
\textbf{Age at diagnosis} & 0.8 & 1.2 & 0.06 & 3.0 & 3.0 & 3.5 & 3.7 & 0.04 \\
\hline
\textbf{Age at start MN (y)} & 2.9 & 4.0 & 2.3 & 9.4 & 4.3 & 5.4 & 6.2 & 4.0 \\
\hline
\textbf{Age at KT (y)} & 3.4 & 4.4 & 4.6 & 10.0 & 5.7 & 6.1 & – & 6.5 \\
\hline
\textbf{RRT mode} & PD & PD & HD & HD & HD & PD & HD & PD \\
\hline
\textbf{Enalapril (mg/kg/d)} & + & + & + & + & + & + & + & + \\
\textbf{Initial dosage} & 0.07 & 0.09 & 0.09 & 0.08 & 0.31 & 0.11 & 0.10 & 0.08 \\
\textbf{Maximum dosage} & 0.15 & 0.40 & 0.09 & 0.76 & 0.37 & 0.22 & 0.10 & 0.08 \\
\hline
\textbf{Indomethacin (mg/kg/d)} & – & – & + & – & – & – & – & + \\
\textbf{Initial dosage} & – & – & 1.15 & – & – & – & – & 1.01 \\
\textbf{Maximum dosage} & – & – & 1.15 & – & – & – & – & 2.02 \\
\hline
\textbf{Diclofenac (mg/kg\textsuperscript{a})} & – & – & – & + & – & – & – & – \\
\textbf{Initial dosage} & – & – & – & 1.52 & – & – & – & – \\
\textbf{Maximum dosage} & – & – & – & 3.05 & – & – & – & – \\
\hline
\textbf{Surgical nephrectomy} & – & – & + & – & – & – & – & + \\
\hline
\textbf{UO before KT} & Reduced & Reduced & Anuria & Reduced & Anuria & Reduced & Reduced & Anuria \\
\hline
\textbf{Serum albumin before MN (g/L)} & 12 & 19 & 11 & 28 & 24 & 17 & 11 & 19 \\
\hline
\textbf{Serum albumin before KT (g/L)} & 30 & 27 & 39 & 33 & 32 & 26 & – & 37 \\
\hline
\textbf{Protein-creatinin ratio after KT\textsuperscript{b}} & 0.30 & 0.42 & 0.25 & 3.63 & 0.33 & 0.40 & NA & 0.70 \\
\hline
\end{tabular}
\caption{Demographics and clinical characteristics of individual patients with ESRD due to nephrotic syndrome who underwent medical nephrectomy}
\end{table}

Abbreviations: CNS, congenital nephrotic syndrome; FSGS, focal segmental glomerular sclerosis; HD, hemodialysis; KT, kidney transplantation; MN, medical nephrectomy; NA, not applicable; PD, peritoneal dialysis; RRT, renal replacement therapy; UO, urine output.

\textsuperscript{a}Dosed after each hemodialysis session.

\textsuperscript{b}9-38 d after KT.
infusion of local anesthetic.\textsuperscript{11,12,19} This method seems to be more invasive, especially in children, frequently needing general anesthesia. In addition, an experienced physician is needed to perform this treatment and there is a risk of injuring the femoral artery, which may hamper arterial anastomosis during kidney transplantation.

Despite the small patient group and the retrospective character, our study supports the use of ACE inhibitors and/or NSAIDs as first-choice therapy in the induction of medical nephrectomy prior to kidney transplantation. Limitations of the present study are the retrospective design, the lack of a hard definition for reduced urine output, the lack of fixed time-points to measure proteinuria and thereby missing data on pretransplant proteinuria, and the small sample size. No conclusions can be drawn regarding indomethacin and diclofenac. Surprisingly, unsuccessful medical nephrectomy seems to be associated with having a NPHS1 gene mutation. Both our patients with NPHS1 gene mutation did not respond to medical nephrectomy, while no other patient needed bilateral surgical nephrectomy. Since such information could not be obtained from other

### TABLE 2

| Urine output | Enalapril (%) | Indomethacin (%) | Enalapril and diclofenac (%) |
|--------------|--------------|-----------------|-----------------------------|
| No difference | 8/8 (100) | 2/8 (25.0) | 1/8 (12.5) |
| Reduced       | 6/8 | 2/2 | 1/1 |
| Anuria        | 1/8 | 0/2 | 0/1 |
| Albumin level (g/L) | 18 (11-28) | 25 (21-29) | 34 |
| Post-medication\textsuperscript{a} | 31 (21-36) | 29 (27-31) | 33 |
| Difference pre- and post-medication\textsuperscript{a} | 12 (2-25) | 4 (-2-10) | -1 |

\textsuperscript{a}Median (range).

### TABLE 3

| Study | Year | N | Disease | Method | Success rate (%) | Side effects |
|-------|------|---|---------|--------|------------------|--------------|
| Medical | | | | | | |
| Baumelou\textsuperscript{17} | 1982 | 1\textsuperscript{a} | Membranous nephropathy | Indomethacin (150 mg/day) | 1/1 | — |
| Hagerty\textsuperscript{18} | 1989 | 1\textsuperscript{a} | Type 1 MPGN | Naproxen (500 mg/day) | 1/1 | — |
| Pomeranz\textsuperscript{14} | 1995 | 1 | Finnish CNS | ACEI (max 5 mg/kg/day) + indomethacin (max 4 mg/kg/day) | 1/1 | — |
| Solak\textsuperscript{13} | 2010 | 1\textsuperscript{a} | NS secondary to amyloidosis | ACEI (80 mg/day) + indomethacin (150 mg/day) | 0/1 | No effect |
| Maeda\textsuperscript{19} | 2011 | 1\textsuperscript{a} | Membranous nephropathy | Indomethacin (max 1000 mg/day) | 0/1 | No effect |
| Sallam\textsuperscript{12} | 2012 | 1\textsuperscript{a} | FSGS | NSAID (high dose) | 0/1 | Gastrointestinal |
| Vos (current) | 2018 | 8 | FSGS, CNS | ACEI, ACEI + diclofenac, indomethacin | 6/8 | Low blood pressure, elevated transaminases |
| Total | | 14 | | | 9/14 (64.3) | |
| Embolization | | | | | | |
| Capozza\textsuperscript{11} | 2007 | 1 | Massive proteinuria | | 1/1 | Flank pain, (fever) |
| Solak\textsuperscript{13} | 2010 | 1\textsuperscript{a} | NS secondary to amyloidosis | | 1/1 | — |
| Maeda\textsuperscript{19} | 2011 | 1\textsuperscript{a} | Membranous nephropathy | | 1/1 | Fever, elevated LDH, WBC, CRP |
| Sallam\textsuperscript{12} | 2012 | 1\textsuperscript{a} | FSGS | | 1/1 | Fever, flank pain, leukocytosis |
| Total | | 4 | | | 4/4 (100) | |

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; CNS, congenital nephrotic syndrome; FSGS, focal segmental glomerular sclerosis; MPGN, membranoproliferative glomerulonephritis; N, number of patients; NS, nephrotic syndrome; NSAID, non-steroidal anti-inflammatory drugs.\textsuperscript{a}Adult.
reports, and it remains to be determined whether this was due to chance or not. Preferably, such information should come from a prospective multi-center study, which is needed to investigate the advantages of ACE inhibitors, possibly in combination with NSAIDs as first-choice therapy in the management of future kidney transplant candidates with proteinuria from the native kidneys.

Since thrombosis is an uncommon outcome, it cannot be determined whether medical nephrectomy decreases the risk of thrombosis post-transplant. Prospectively showing improvements in clotting factors such as ATIII would be useful in future studies. Another potential pitfall of medical nephrectomy could be the recurrence of proteinuria after transplantation. We did not observe any rebound proteinuria, which may be explained by the use of tacrolimus as part of the immunosuppressive regimen, as tacrolimus is well known to result in vasoconstriction of the afferent arterioles, with a subsequent reduction in glomerular permeability to protein and thereby a reduction of proteinuria.20

Based on the presented data, we conclude that medical nephrectomy with ACE inhibitors and/or NSAIDs should have a place in the process prior to renal transplantation before surgical or embolization nephrectomy. Since our study was limited to 8 patients, we acknowledge that complications may still occur and patients should be on close monitoring. However, these data suggest that complications other than standard (side) effects of the medication is mediated in as rare and treatment can be started safely, starting with a low dose of 0.1 mg/kg/d of enalapril.

AUTHORS’ CONTRIBUTIONS
Michiel F. Schreuder, Elisabeth A. M. Cornelissen, Linda Koster-Kamphuis, Nicole C. A. J. van de Kar, and Charlotte M. H. H. T Bootsmia-Robroeks: conceived case series; Eefke Vos and Michiel F. Schreuder: designed the case series; Michiel F. Schreuder, Linda Koster-Kamphuis, Charlotte M. H. H. T. Bootsmia-Robroeks, and Elisabeth A. M. Cornelissen: helped including cases; Eefke Vos: coordinated the running of the case series, the data collection, and carried out the initial statistical analysis. Eefke Vos: wrote the first draft of the manuscript. Michiel F. Schreuder: assisted Eefke Vos with further analysis and contributed to the interpretation of the analysis and the writing of the manuscript. All authors contributed in revising the manuscript. All authors read and approved the final manuscript.

ORCID
Elisabeth A. M. Cornelissen https://orcid.org/0000-0002-1156-5264
Michiel F. Schreuder https://orcid.org/0000-0001-9725-4856

REFERENCES
1. Huttenen NP. Congenital nephrotic syndrome of Finnish type. Study of 75 patients. Arch Dis Child. 1976;51(5):344-348.
2. Berody S, Heidet L, Gribouval O, et al. Treatment and outcome of congenital nephrotic syndrome. Nephrol Dial Transplant. 2018;34(3):458-467.
3. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr. 2009;155(1):105.e1-110.e1.
4. Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32(1):157-164.
5. Carlier M, Squifflet JP, Pirson Y, Decoca L, Gribomont B, Alexandre GP. Confirmation of the crucial role of the recipient’s maximal hydration on early diuresis of the human cadaver renal allograft. Transplantation. 1983;36(4):455-456.
6. Sener A, Bella AJ, Nguan C, Luke PPW, House AA. Focal segmental glomerulosclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant. 2009;23(1):96-100.
7. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int. 2012;25(9):909-917.
8. Ghane Sharbaf F, Bitzan M, Szymanski KM, et al. Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects. Pediatr Nephrol. 2012;27(7):1179-1188.
9. Bennett WM. Cost-benefit ratio of pretransplant bilateral nephrectomy. JAMA. 1976;235(16):1703-1704.
10. Corkum KS, Baumann LM, Lautz TB. Compensation rates for pediatric hepatectomy and nephrectomy: a comparison of NSQIP-P, PHIS, and KID. J Surg Res. 2019;240:182-190.
11. Capozza N, Collura G, Falappa P, Caione P. Renal embolization as an alternative to surgical nephrectomy in children. Transplant Proc. 2007;39(6):1782-1784.
12. Sallam HE, El-Reshaid K, Varro J. Renal ablation using bilateral renal artery embolization for treatment of resistant nephrotic syndrome. Saudi J Kidney Dis Transpl. 2012;23(6):1258-1261.
13. Solak Y, Polat I, Atalay H, Turk S. When urine is no longer beneficial: renal artery embolisation in severe nephrotic syndrome secondary to amyloidosis. Amyloid. 2010;17(1):24-26.
14. Pomeranz A, Wolach B, Bernheim J, Korzets Z, Bernheim J. Successful treatment of Finnish congenital nephrotic syndrome with captopril and indomethacin. J Pediatr. 1995;126(1):140-142.
15. Lama G, Luongo I, Piscitelli A, Salsano ME. Enalapril: antiproteinuric effect in children with nephrotic syndrome. Clin Nephrol. 2000;53(6):432-436.
16. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987;32(1):78-83.
17. Baumelou A, LeGrain M. Medical nephrectomy with anti-inflammatory non-steroidal drugs. Br Med J (Clin Res Ed). 1982;284(6311):234.
18. Hagerty DT, Snyder JP, Patel TG. Type I MPGN in a renal allograft causing end-stage renal disease with persistent nephrotic syndrome. Medical nephrectomy using naproloxin. Transplantation. 1989;48(4):702-704.
19. Maeda A, Takeda K, Kondou H, et al. Percutaneous renal artery embolization in a patient with severe nephrotic syndrome which continued after the introduction of hemodialysis. Intern Med. 2011;50(23):2899-2904.
20. Naesens M, Kyupers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481-508.